For research use only. Not suitable for human use.
Isotype
(scFv-kappa-heavy)-(scFv-heavy-kappa); His-Tag
Description of Blinatumomab Biosimilar – Anti-CD19/CD3E Bispecific Antibody (Research Grade)
Blinatumomab biosimilar is a recombinant bispecific antibody targeting CD19 and CD3E, developed for research applications in immuno-oncology and T-cell engager studies. This research-grade antibody reproduces the mechanism of action of Blinatumomab by redirecting cytotoxic T cells toward CD19-expressing B cells.
Produced under strict quality control, this recombinant antibody is suitable for a wide range of immunotherapy, leukemia, and lymphoma research studies.
ProteoGenix provides high-quality research antibodies at competitive pricing, enabling laboratories to access reliable reagents for advanced immunology and oncology research.
Pricing and Availability
This Blinatumomab biosimilar antibody is available for research use with flexible purchasing options depending on quantity and project requirements.
SDS-PAGE for Blinatumomab Biosimilar - Anti-CD19, CD3E mAb - Research Grade
Blinatumomab Biosimilar - Anti-CD19, CD3E mAb - Research Grade on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue.. The purity of the antibody is greater than 95%.
Publication
Park AK, Monroy I, Ren Y, Lu C, Chaurasiya S, Valencia H, et al. Universal off-the-shelf combination immunotherapy using oncolytic viruses to redirect T cell engagers to target solid tumors. Journal for ImmunoTherapy of Cancer. 2025;13:e011051. https://doi.org/10.1136/jitc-2024-011051
Reviews
There are no reviews yet.
REVIEW YOUR PRODUCT
Be the first to review “Blinatumomab Biosimilar – Anti-CD19/CD3E Bispecific Antibody (Research Grade)” Cancel reply
Reviews
There are no reviews yet.